<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03524976</url>
  </required_header>
  <id_info>
    <org_study_id>Liquid</org_study_id>
    <nct_id>NCT03524976</nct_id>
  </id_info>
  <brief_title>Treatment of Dural Arteriovenous Fistulas With SQUID™ Liquid Embolic Agent</brief_title>
  <acronym>Liquid</acronym>
  <official_title>LIQUID - Treatment of Dural Arteriovenous Fistulas With SQUID™ Liquid Embolic Agent, A Non-interventional, Observational, Prospective and Multi-center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Markus Alfred Möhlenbruch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is assessment of safety, efficacy, and short-term outcome of SQUID™
      in the embolization of Dural Arteriovenous Fistula
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Traditionally, there are two therapeutic options for the treatment of Dural Arteriovenous
      Fistula (DAVF): (1) the surgical approach consisting of craniotomy and ligation of the vein
      and (2) the endovascular approach with embolization of shunting zone. Onyx™ (EVOH (Ethylene
      Vinyl Alcohol) in solution in an organic solvent, DMSO (Dimethyl Sulfoxide), is the main
      embolic agent used for the endovascular treatment of DAVF. During the occlusion procedure
      with Onyx™, residual malformed compartments become gradually less visible on x-ray to the
      operator, due to the high radiopacity of Onyx™, resulting in a potential risk during
      treatment. Moreover, viscosity is frequently not as low as required to penetrate the
      shunt.Thus, development a new embolization system with lower radiopacity and lower viscosity
      to achieve improved occlusion is needed. SQUID™ is a new liquid embolic agent, with variable
      radiopacity and viscosity. The purpose of this study is assessment of safety, efficacy, and
      short-term outcome of SQUID™ in the embolization of DAVFs .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Morbidity/Mortality</measure>
    <time_frame>90-180 days after treatment</time_frame>
    <description>number of patients with permanent morbidity or mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occlusion rate</measure>
    <time_frame>90 -180 days after treatment</time_frame>
    <description>number of patients with complete occlusion of the treated Dural Arteriovenous Fistula</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DAVF anatomy</measure>
    <time_frame>Baseline / day 0-1</time_frame>
    <description>Anatomical description of the Dural Arteriovenous Fistula using Lariboisiere classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>modified Rankin Score</measure>
    <time_frame>Baseline / day 0-1</time_frame>
    <description>Baseline mRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Approach</measure>
    <time_frame>Treatment / day 1</time_frame>
    <description>approach path (vessel)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feeders</measure>
    <time_frame>Treatment / day 1</time_frame>
    <description>number of feeders embolized,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Squid</measure>
    <time_frame>Treatment / day 1</time_frame>
    <description>volume and concentration of SQUID™ injected at each embolization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ballons</measure>
    <time_frame>Treatment / day 1</time_frame>
    <description>Binary: for access to DAVF was a balloon catheter used / no balloon used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coils</measure>
    <time_frame>Treatment / day 1</time_frame>
    <description>If complete occlusion was not achieved using Squid: Binary Outcome: use of coils or no use of coils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other</measure>
    <time_frame>Treatment / day 1</time_frame>
    <description>If complete occlusion was not achieved using Squid: Binary Outcome: use of other embolization agent / no other agent used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immediate Aneurysm Occlusion</measure>
    <time_frame>Treatment / Day 1</time_frame>
    <description>50-99% occlusion
&lt; 50% occlusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-Up Aneurysm Occlusion</measure>
    <time_frame>90-180 days after treatment</time_frame>
    <description>50-99% occlusion
&lt; 50% occlusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional health status</measure>
    <time_frame>90-180 days after treatment</time_frame>
    <description>based on modified Rankin Scale</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Dural Arteriovenous Fistula</condition>
  <arm_group>
    <arm_group_label>Embolization with Squid</arm_group_label>
    <description>All patients with DAVFs are treated with SQUID™ aiming at complete occlusion of the fistula. Each participating center will include patients with DAVFs in whom the liquid embolic agent SQUID™ is planned to be used consecutively in the study. The</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Squid</intervention_name>
    <description>SQUID™ is injected into the vascular site to be treated, under fluoroscopic control. DMSO dissipates in the blood and causes precipitation of EVOH in which the tantalum powder is trapped. It then forms a consistent spongy embolus.
This embolus solidifies from the outside inwardly while moving distally in the vessel. The non-adhesive character of the embolus allows slow and controlled injections while leaving in place the microcatheter.</description>
    <arm_group_label>Embolization with Squid</arm_group_label>
    <other_name>non-adhesive liquid embolic agent</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with Dural Arteriovenous Fistulas who will be treated with SQUID™ aiming at
        complete occlusion of the fistula. Each participating center will include patients with
        DAVFs in whom the liquid embolic agent SQUID™ is planned to be used consecutively in the
        study. The patient cohort will include patients with DAVFs who had not undergone any
        previous treatment with an embolic agent whatsoever.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Dural Arteriovenous Fistula requiring endovascular treatment with a Lariboisiere score
             between 3 - 5

               -  Intended usage of SQUID™

               -  The patient agrees with the clinical data collection and medical file access.

        Exclusion Criteria:

          -  DAVF with a Lariboisiere score &lt; 3 • Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Moehlenbruch, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susanne Bonekamp, DVM, PhD</last_name>
    <phone>+4962215635710</phone>
    <email>susanne.bonekamp@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lukas Diebold</last_name>
    <email>lukas.diebold@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klnikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ansgar Berlis, Prof Dr. med</last_name>
      <email>ansgar.berlis@klinikum-augsburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinische und interventionelle Neuroradiologie Vivantes Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Bock, MD</last_name>
      <email>alexander.bock@vivantes.de</email>
    </contact>
    <investigator>
      <last_name>Alexander Bock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité-Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Liebig, MD</last_name>
      <phone>+49(0)30-450-557192</phone>
      <email>thomas.liebig@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinic Bochum</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Werner Weber, Prof Dr.</last_name>
      <email>werner.weber@kk-bochum.de</email>
    </contact>
    <investigator>
      <last_name>Werner Weber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gesundheit Nord gGmbH Klinikverbund Bremen</name>
      <address>
        <city>Bremen</city>
        <zip>28211</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Panagiotis Papanagiotou, PD Dr.</last_name>
      <phone>0049 4214082523</phone>
      <email>panagiotis.papanagiotou@klinikum-bremen-mitte.de</email>
    </contact>
    <investigator>
      <last_name>Panagiotis Papanagiotou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfried Krupp Krankenhaus Rüttenscheid</name>
      <address>
        <city>Essen</city>
        <zip>45131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>René Chapot, MD</last_name>
      <phone>0049201 43441629</phone>
      <email>rene.chapot@krupp-krankenhaus.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik für Neuroradiologie Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Bergmann</last_name>
      <email>ulrike.bergmann@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Stephan Meckel, Prof Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Cognard C, Gobin YP, Pierot L, Bailly AL, Houdart E, Casasco A, Chiras J, Merland JJ. Cerebral dural arteriovenous fistulas: clinical and angiographic correlation with a revised classification of venous drainage. Radiology. 1995 Mar;194(3):671-80.</citation>
    <PMID>7862961</PMID>
  </reference>
  <reference>
    <citation>Narayanan S. Endovascular management of intracranial dural arteriovenous fistulas. Neurol Clin. 2010 Nov;28(4):899-911. doi: 10.1016/j.ncl.2010.03.013. Review.</citation>
    <PMID>20816269</PMID>
  </reference>
  <reference>
    <citation>Rammos S, Bortolotti C, Lanzino G. Endovascular management of intracranial dural arteriovenous fistulae. Neurosurg Clin N Am. 2014 Jul;25(3):539-49. doi: 10.1016/j.nec.2014.04.010. Epub 2014 Jun 2. Review.</citation>
    <PMID>24994089</PMID>
  </reference>
  <reference>
    <citation>Li C, Yang X, Li Y, Jiang C, Wu Z. Endovascular Treatment of Intracranial Dural Arteriovenous Fistulas Presenting with Intracranial Hemorrhage in 46 Consecutive Patients: With Emphasis on Transarterial Embolization with Onyx. Clin Neuroradiol. 2016 Sep;26(3):301-8. doi: 10.1007/s00062-014-0362-y. Epub 2014 Dec 13.</citation>
    <PMID>25501269</PMID>
  </reference>
  <reference>
    <citation>Cognard C, Januel AC, Silva NA Jr, Tall P. Endovascular treatment of intracranial dural arteriovenous fistulas with cortical venous drainage: new management using Onyx. AJNR Am J Neuroradiol. 2008 Feb;29(2):235-41. Epub 2007 Nov 7.</citation>
    <PMID>17989374</PMID>
  </reference>
  <reference>
    <citation>Chiu AH, Aw G, Wenderoth JD. Double-lumen arterial balloon catheter technique for Onyx embolization of dural arteriovenous fistulas: initial experience. J Neurointerv Surg. 2014 Jun;6(5):400-3. doi: 10.1136/neurintsurg-2013-010768. Epub 2013 Jun 8.</citation>
    <PMID>23749795</PMID>
  </reference>
  <reference>
    <citation>Adamczyk P, Amar AP, Mack WJ, Larsen DW. Recurrence of &quot;cured&quot; dural arteriovenous fistulas after Onyx embolization. Neurosurg Focus. 2012 May;32(5):E12. doi: 10.3171/2012.2.FOCUS1224.</citation>
    <PMID>22537121</PMID>
  </reference>
  <reference>
    <citation>Ambekar S, Gaynor BG, Peterson EC, Elhammady MS. Long-term angiographic results of endovascularly &quot;cured&quot; intracranial dural arteriovenous fistulas. J Neurosurg. 2016 Apr;124(4):1123-7. doi: 10.3171/2015.3.JNS1558. Epub 2015 Sep 25.</citation>
    <PMID>26406789</PMID>
  </reference>
  <reference>
    <citation>Akmangit I, Daglioglu E, Kaya T, Alagoz F, Sahinoglu M, Peker A, Derakshani S, Dede D, Belen D, Arat A. Preliminary experience with squid: a new liquid embolizing agent for AVM, AV fistulas and tumors. Turk Neurosurg. 2014;24(4):565-70. doi: 10.5137/1019-5149.JTN.11179-14.0.</citation>
    <PMID>25050683</PMID>
  </reference>
  <reference>
    <citation>Abud TG, Nguyen A, Saint-Maurice JP, Abud DG, Bresson D, Chiumarulo L, Enesi E, Houdart E. The use of Onyx in different types of intracranial dural arteriovenous fistula. AJNR Am J Neuroradiol. 2011 Dec;32(11):2185-91. doi: 10.3174/ajnr.A2702. Epub 2011 Sep 29.</citation>
    <PMID>21960490</PMID>
  </reference>
  <reference>
    <citation>Chandra RV, Leslie-Mazwi TM, Mehta BP, Yoo AJ, Rabinov JD, Pryor JC, Hirsch JA, Nogueira RG. Transarterial onyx embolization of cranial dural arteriovenous fistulas: long-term follow-up. AJNR Am J Neuroradiol. 2014 Sep;35(9):1793-7. doi: 10.3174/ajnr.A3938. Epub 2014 Apr 17.</citation>
    <PMID>24742807</PMID>
  </reference>
  <reference>
    <citation>Gross BA, Albuquerque FC, Moon K, McDougall CG. Evolution of treatment and a detailed analysis of occlusion, recurrence, and clinical outcomes in an endovascular library of 260 dural arteriovenous fistulas. J Neurosurg. 2017 Jun;126(6):1884-1893. doi: 10.3171/2016.5.JNS16331. Epub 2016 Sep 2.</citation>
    <PMID>27588586</PMID>
  </reference>
  <reference>
    <citation>Gallas S, Drouineau J, Gabrillargues J, Pasco A, Cognard C, Pierot L, Herbreteau D. Feasibility, procedural morbidity and mortality, and long-term follow-up of endovascular treatment of 321 unruptured aneurysms. AJNR Am J Neuroradiol. 2008 Jan;29(1):63-8. Epub 2007 Oct 9.</citation>
    <PMID>17925369</PMID>
  </reference>
  <reference>
    <citation>Hsu YH, Lee CW, Liu HM, Wang YH, Chen YF. Endovascular treatment and computed imaging follow-up of 14 anterior condylar dural arteriovenous fistulas. Interv Neuroradiol. 2014 May-Jun;20(3):368-77. doi: 10.15274/NRJ-2014-10028. Epub 2014 Jun 17.</citation>
    <PMID>24976101</PMID>
  </reference>
  <reference>
    <citation>Long XA, Karuna T, Zhang X, Luo B, Duan CZ. Onyx 18 embolisation of dural arteriovenous fistula via arterial and venous pathways: preliminary experience and evaluation of the short-term outcomes. Br J Radiol. 2012 Aug;85(1016):e395-403. doi: 10.1259/bjr/25192972. Epub 2012 Feb 28.</citation>
    <PMID>22374275</PMID>
  </reference>
  <reference>
    <citation>Maimon S, Nossek E, Strauss I, Blumenthal D, Frolov V, Ram Z. Transarterial treatment with Onyx of intracranial dural arteriovenous fistula with cortical drainage in 17 patients. AJNR Am J Neuroradiol. 2011 Dec;32(11):2180-4. doi: 10.3174/ajnr.A2728. Epub 2011 Oct 13.</citation>
    <PMID>21998110</PMID>
  </reference>
  <reference>
    <citation>van Rooij WJ, Sluzewski M. Curative embolization with Onyx of dural arteriovenous fistulas with cortical venous drainage. AJNR Am J Neuroradiol. 2010 Sep;31(8):1516-20. doi: 10.3174/ajnr.A2101. Epub 2010 Apr 15.</citation>
    <PMID>20395390</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2018</study_first_submitted>
  <study_first_submitted_qc>May 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2018</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Dr. Markus Alfred Möhlenbruch</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>endovascular treatment</keyword>
  <keyword>liquid embolization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fistula</mesh_term>
    <mesh_term>Arteriovenous Fistula</mesh_term>
    <mesh_term>Central Nervous System Vascular Malformations</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

